Update on Treatment of Type 1 Diabetes in Childhood

被引:0
作者
Ludvigsson J. [1 ]
机构
[1] Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping University, 58185, Linköping
关键词
C-peptide; Closed loop; GAD; Immune intervention; Monoclonal antibodies; Type; 1; diabetes;
D O I
10.1007/s40124-013-0012-x
中图分类号
学科分类号
摘要
After 90 years of using insulin to treat type 1 diabetes, there has been no radical change in the treatment. Although several discoveries have improved both quality of life and metabolic control, they have not eradicated, morbidity, and mortality. Insulin analogues are sometimes helpful, and pens, pumps, smart glucometers, and educational tools have facilitated and improved treatment. Soon, better insulin pumps and glucose sensors together with sophisticated algorithms and connections leading to closed-loop systems will probably further improve and facilitate treatment of many patients with type 1 diabetes. However, the burden for patients will not disappear completely, and modern therapy will still require both competence and motivation of patients. Therefore, the goal should be either to cure the disease via replacement therapy (transplantations) or to stop the destructive process, preserve residual insulin secretion, or even improve insulin secretion via beta-cell regeneration. This will result in a milder disease, a stabler metabolism, simpler treatment, and perhaps even cure. Several studies are ongoing, but nothing has proved useful so far in clinical practice. © 2013, Springer Science + Business Media New York.
引用
收藏
页码:118 / 127
页数:9
相关论文
共 84 条
[1]  
Aanstoot H.J., Anderson B.J., Daneman D., Danne T., Donaghue K., Kaufman F., Rea R.R., Uchigata Y., The global burden of youth diabetes: perspectives and potential, Pediatr Diabetes, 8, pp. 1-44, (2007)
[2]  
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, pp. 977-986, (1993)
[3]  
Bojestig M., Arnqvist H.J., Hermansson G., Karlberg B.E., Ludvigsson J., Declining incidence of nephropathy in insulin-dependent diabetes mellitus, N Engl J Med, 330, pp. 15-18, (1994)
[4]  
Wild D., Von Maltzahn R., Brohan E., Christensen T., Clauson P., Gonder-Frederick L., A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education, Patient Educ Couns, 68, pp. 10-11, (2007)
[5]  
Harjutsalo V., Forsblom C., Groop PH Time trends in mortality in patients with type 1 diabetes: Nationwide population based cohort study, BMJ, 343, (2011)
[6]  
Danne T., Aman J., Schober E., Deiss D., Jacobsen J.L., Friberg H.H., Jensen LH
[7]  
ANA 1200 Study Group A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes, Diabetes Care, 26, 8, pp. 2359-2364, (2003)
[8]  
Chase H.P., Arslanian S., White N.H., Tamborlane W.V., Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus, J Pediatr, 153, 4, pp. 547-553, (2008)
[9]  
Monami M., Marchionni N., Mannucci E., Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis, Diabetes Obes Metab, 11, 4, pp. 372-378, (2009)
[10]  
Danne T., Datz N., Endahl L., Haahr H., Nestoris C., Westergaard L., Fjording M.S., Kordonouri O., Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial, Pediatr Diabetes, 9, 6, pp. 554-560, (2008)